- Българският туристически портал
Русская версия Българска версия
Новини от бранша


Actavis growing in double digits in Bulgaria

Date: 31.08.2007

Actavis Group, the international generic pharmaceuticals company, announced in Tuesday that Actavis is growing in double digits in Bulgaria through its broad product portfolio, reaching 10,65% in the first half with over EUR EUR23.1 million in sales of its own label products. According to IMS data, Actavis Bulgaria remains the largest generic pharmaceuticals company in Bulgaria.

Despite low market growth on Rx site and enormous price erosion in the market, Actavis has managed to deliver double digits growth in sales over 2006 through using cross selling opportunities and new OTC and food supplements launches.

Actavis Bulgaria has launched a record number of 24 new products during the first half of the year. Over 20 more are expected to be launched until the end of the year 2007. The growth is also supported by the dynamic product pipeline and highly motivated sales force team of over 70 people.

“Actavis Bulgaria has a good start of the year in line with our expectation. We continue to benefit of our strong product pipeline which has resulted in significant product launch activity”, Managing Director of Actavis Bulgaria Nikolay Hadzhidonchev said commenting on the results.

“Our strong focus on sales management together with cost reduction and efficiency improvement initiatives contributed to the good performance of the Bulgarian team,” Hadzhidonchev added.

Total views: 3 rating: 1.50
traveller's forum
No opinions

We've tried to make the information on this web site as accurate as possible, but it is provided 'as is' and we accept no responsibility for any loss, injury or inconvenience sustained by anyone resulting from this information. You should verify critical information (like visas, health and safety, customs and transportation) with the relevant authorities before you travel.

Journey Bulgaria | News | Actavis growing in double digits in Bulgaria
© 2000-2018 All rights reserved.